Cholinergic deficits in Alzheimer's disease are typically assessed by choline acetyltransferase, the enzyme that synthesizes acetylcholine. However, the determining step in acetyl-
Introduction
Alzheimer's disease, morphologically characterized by the abnormal presence of senile plaques and neurofibrillary tangles, is distinguished neuroanatomically by the loss of cholinergic projections to the cerebral cortex, a deficit that has provided a focus for studies of potential therapies for cognitive defects (1) (2) (3) . Unfortunately, the rapid postmortem degradation of acetyl-choline has rendered it virtually impossible to evaluate directly how the disease affects levels or turnover of this transmitter. Accordingly, studies have focused on choline acetyltransferase (acetyl-CoA:choline O-acetyltransferase, EC 2.3.1.6), the enzyme that synthesizes acetylcholine from choline and acetyl CoA, and on the high affinity choline transporter that takes up choline from the synapse and translocates it to the presynaptic terminal. Although nearly all investigations show that Alzheimer's disease is characterized by loss of choline acetyltransferase (1) (2) (3) , this enzyme is not the rate-limiting step in acetylcholine biosynthesis and its activity is not affected by changes in neuronal activity (4) (5) (6) ; thus, the reduction of choline acetyltransferase activity substantiates the loss of cholinergic nerve terminals but gives no indication of the state of cholinergic function of the remaining terminals.
The issue of cholinergic function in brain regions damaged by Alzheimer's disease is vital to understanding both the origins and potential therapy of cognitive impairment. The loss of dopaminergic function in Parkinson's disease does not lead to overt symptoms until the majority of nerve terminals has degenerated and even then can be offset by administration of the dopamine precursor, L-dopa (7); the treatment enables sufficient dopamine synthesis to keep pace with increased impulse activity that offsets the deficiency in the number of nerve terminals. In contrast, administering choline, the precursor to acetylcholine, has produced variable but largely disappointing results in Alzheimer's disease (for review see reference 3), despite the fact that deficits in choline acetyltransferase indicate a smaller synaptic loss than the dopaminergic deficit in Parkinson's disease (8) . This disparity suggests that the cholinergic neurons have a limitation in their ability to acquire or use choline (1) that transcends the straightforward strategy of simply providing an increase in dietary intake of the appropriate neurotransmitter precursor. To an extent, this reflects basic differences in the biosynthetic steps leading to formation of dopamine as compared with acetylcholine. Dopamine is formed from L-dopa by L-aromatic amino acid decarboxylase, which is in plentiful supply in a wide variety of cells. Acetylcholine can be formed from choline only in cholinergic neurons. Therefore, it is of critical importance that the rate-limiting step in acetylcholine synthesis is the uptake of choline from the synapse and that the activity of the high affinity transporter, located solely on cholinergic nerve terminals, is directly affected by neuronal impulses (4) (5) (6) . In animal studies, upregulation of choline transport is readily obtained after manipulations that enhance cholinergic tone (4, 6, 9, 10) . However, this step has rarely been evaluated in Alzheimer's disease because measurement of choline uptake requires the isolation of nerve terminal particles (synaptosomes) that maintain their viability for only a short period after death; indeed, the component of choline transport specifically associated with increased neuronal impulse activity decays the most rapidly (11) . By ob-taining synaptosomes within 2 h postmortem, we have recently found that choline uptake in cortical regions of patients with Alzheimer's disease is not decreased, but rather is elevated (12) ; in keeping with the rapid decay of the impulse-activity-related component of uptake, the elevation is not found when the postmortem wait is prolonged (2, 13) . These results suggest that, in Alzheimer's disease, the remaining cholinergic nerve terminals are attempting to compensate for synaptic loss by increasing their capacity to take up choline, yet, unlike the situation for dopaminergic function in Parkinson's disease, they fail to make up for the deficit.
A number of uncertainties exist in evaluating the origin and meaning of the changes in high affinity choline uptake in Alzheimer's disease. The uptake process involves not only the activity of the choline transporter itself, but also the metabolic status of the terminal (to provide the driving energy for transport), factors influencing the choline concentration gradient (removal of free cytoplasmic choline by its incorporation into acetylcholine and phospholipids), packaging of acetylcholine in synaptic vesicles, and leakage of choline back into the synapse. As a first step in delineating the contribution of each of these factors, the current study evaluates expression of the transporter, as evaluated with the specific radioligand, [3H] (1 with amyotrophic lateral sclerosis, I with gliosis, and 5 with cancers not involving the nervous system). None of the patients received anticholinergic or antihistaminic medications during the week before death. The methods for patient recruitment into the program and the standard protocols for terminal care (including 100% oxygen by nasal prongs and oral or intravenous fluids) were approved by the Duke University Medical Center Institutional Review Board.
To meet the criteria for rapid autopsy, the postmortem delay from the time of death to freezing of tissues on dry ice was under 4 h; in fact, only two samples were obtained at more than 2 h postmortem. Approximately 1 g of gray matter was removed from the superior frontal gyrus, the superior parietal lobule, and the putamen. Adjacent sections from each neocortical area were submitted for histological analysis by techniques described previously (12) ; paraffin sections were stained with hematoxylin and eosin with a Luxol fast blue counterstain for myelin, a silver stain for neuritic plaques and neurofibrillary tangles, and a Congo red stain for amyloid. By these criteria, the Alzheimer's disease group could be clearly distinguished from the controls (cortical plaques/ mm2 = 44--3 vs. l±+2 in controls, P < 0.0001; cortical tangles/mm2 = 9+2 vs. 0±0 in controls, P < 0.0005).
Tissue preparation and biochemical assays. Tissues were stored at -80°C until analysis; preliminary studies showed no degradation of choline acetyltransferase activity or [3H]hemicholinium-3 binding characteristics after storage (data not shown); in addition, samples were compared from the same patients in a previous study of choline acetyltransferase activity (12) , and activity was found to be unchanged after as much as 7 yr of storage. Whenever possible, samples from patients in the control and Alzheimer's disease groups were run concurrently.
Tissues 
Results
The limited availability of preselected individuals and the rigorous requirements to enable rapid autopsy to take place do not provide a prospective framework for specific matching of patient variables. Accordingly, the population of controls available in this study differed in several aspects from the population with a diagnosis of Alzheimer's disease (Table I) . First, whereas the Alzheimer's disease cohort had a predominance of females, the controls had more males. In addition, the controls tended to be slightly younger, and tissues were obtained with a somewhat longer postmortem delay time. Accordingly, where biochemical variables exhibited significant differences between the two cohorts, regression analyses also were conducted to evaluate whether these three potential confounding factors contributed to the differences (see below).
In keeping with the major cholinergic defect associated with Alzheimer's disease (12, (21) (22) (23) , choline acetyltransferase activity was severely reduced in cortical regions, whereas the putamen, a region generally unaffected by the disease, displayed normal values for enzyme activity (Fig. 1) Putamen Figure 1 . Choline acetyltransferase activity in rapid autopsy tissue obtained from controls (CON) and patients with Alzheimer's disease (ALZ). Two-factor ANOVA across all three regions indicates a significant main effect of diagnosis (P < 0.009) and interaction of diagnosis x region (P < 0.005). ANOVAs conducted separately for the two cortical regions and for the putamen are shown within the panels, and asterisks denote significant differences from corresponding control values. In addition, the effect in the frontal cortex is distinguishable from that in the putamen (interaction of diagnosis x region, P < 0.04), as is the effect in the parietal cortex (P < 0.03). Effects in frontal cortex are equivalent to those in parietal cortex (no interaction of diagnosis x region).
conclusions; calculated values for frontal cortex, parietal cortex, and putamen were 2.9, 1.9, and 84 nmol/h per mg protein, respectively, which were not significantly different from the actual control values but were significantly different from the cortical values in the Alzheimer's group (frontal cortex, P < 0.001; parietal cortex, P < 0.005; putamen, NS). Although nonspecific binding was as much as 65% in membrane preparations from cortical regions, reliable Scatchard determinations of the binding of [3H]hemicholinium-3 to the high affinity choline transporter were obtained nonetheless (Fig. 2) , in large part because of the plentiful amount of tissue available from human brain. Despite the loss of cortical cholinergic nerve terminals exemplified by the decline in choline acetyltransferase activity, the number of binding sites (B,,,-) was enhanced significantly in the frontal cortex of the Alzheimer's disease group (Fig. 3) . There was no change in the putamen, a region presumptively not involved in the cholinergic degeneration associated with Alzheimer's disease; values in the parietal cortex were not distinguishable either from those in frontal cortex or putamen. As was true for choline acetyltransferase activity, these conclusions were unchanged when multiple regression was used to identify whether the intergroup differences in sex (r = 0.07, NS), age (r = 0.05, NS), and postmortem delay (r = 0.02, NS) contributed to the apparent effect of the disease. Extrapolating control values matched to the sex, age, and postmortem delay of the Alzheimer's disease group produced calculated values for Bmax of 16 fmol/mg protein in frontal cortex, 16 in parietal cortex, and 268 in putamen; using these values to determine significant differences led to the same conclusion, namely a significant increase in B,|, caused by the disease in frontal cortex (P < 0.02) but not in the other regions.
The binding affinity (Kd) of [3H]hemicholinium-3 to the choline transporter was not significantly altered by Alzheimer's disease (Fig. 4) Figure 3. [3H]Hemicholinium-3 binding capacity (B,..o) in rapid autopsy tissue obtained from controls (CON) and patients with Alzheimer's disease (ALZ). Two-factor ANOVA across all three regions indicates a significant main effect of diagnosis (P < 0.003). ANOVAs conducted separately for the two cortical regions and for the putamen are shown within the panels, and the asterisk denotes a significant difference from the corresponding control value. In addition, the effect in the frontal cortex is distinguishable from that in the putamen (interaction of diagnosis x region, P < 0.05), but the effect in the parietal cortex is not distinguishable from either that in the putamen or in the frontal cortex. (19, 20) . Expressed as a ratio, the robust upregulation of transporter sites was clearly present in both cortical regions but not in the putamen (Fig. 5) . The effect in parietal cortex was not distinguishable from that in frontal cortex, but both cortical regions were collectively and individually distinguishable from the lack of upregulation in the putamen. Multiple regression analysis showed that the sex, age, and postmortem delay differences between the control and Alzheimer's disease populations did not account for the differences (r = -0.005, 0.02, and -0.02, respectively; all NS), nor did the summation of small contributions of these variables invalidate the conclusions. . Two-factor AN-OVA across all three regions indicates a significant main effect of diagnosis (P < 0.0001) and an interaction of diagnosis x region (P < 0.0008). ANOVAs conducted separately for the two cortical regions and for the putamen are shown within the panels, and asterisks denote significant differences from corresponding control values. In addition, the effect in the frontal cortex is distinguishable from that in the putamen (interaction of diagnosis x region, P < 0.0003), as is the effect in the parietal cortex (P < 0.004). Effects in frontal cortex are equivalent to those in parietal cortex (no interaction of diagnosis x region).
diagnostic categories (P < 0.01 for both) whereas the putamen was not different.
To ensure that changes in choline acetyltransferase activity or [3H]hemicholinium-3 binding attributable to Alzheimer's disease did not reflect differences in tissue integrity or in recovery of membranes used in the binding studies, comparisons were made of total tissue protein and membrane protein (Fig. 6) . Although the Alzheimer's disease group showed a significant overall elevation in total protein, the effect was quite small (-7%) and showed none of the regional selectivity characteristic of the specific cholinergic markers. Although population differences in sex, age, and postmortem delay did not produce significant correlations by themselves (r = -0.08, 0.02, and -0.19, respectively; all NS), the summation of these small effects actually accounted for the entire difference in total protein. (25) , suggesting that enhanced choline transport capabilities cannot compensate fully for the underlying defects. A further test of this relationship exists outside the framework of a neurodegenerative disease. During brain development, where increased demand for choline is associated with the need for expansion of the membrane surface in association with axonal outgrowth, the high affinity choline transporter is also overexpressed both relative to choline acetyltransferase activity and in terms of absolute activity (19, 20) . Transporter expression during developmental membrane expansion is likewise superimposed on changes related to cholinergic nerve impulse activity (18, 20, 26) . However, unlike the case in Alzheimer's disease, the developmental overexpression is accompanied by increased choline availability (27) . Our results represent an apparent contradistinction from previous reports of [3H]hemicholinium-3 binding site in standard autopsy material, which show a general decrease in binding in cortical regions and hippocampus in Alzheimer's disease, albeit not as much a proportional decrease as is typically found for choline acetyltransferase (28) . These differences are most likely attributable to short versus prolonged postmortem delay in obtaining the tissues.
[3H]Hemicholinium-3 binding falls off by 20-40% in the first 4 h postmortem and declines significantly even with immediate cooling of the brain (29) . It is therefore critical to note that, based on studies of high affinity choline uptake by the transporter, it is precisely the upregulation associated with elevated impulse activity that decays the most rapidly after death (11) . Using tissue from rapid autopsy, we have shown that choline uptake is elevated in cortical regions of Alzheimer's disease patients (12) , whereas after a lengthy postmortem wait, the elevation is lost (2, 13). The results obtained from rapid autopsy are thus more likely to correspond to the actual conditions present in the intact presynaptic terminal because they exhibit activity-related changes whereas the samples obtained after a delay do not. In concert with this interpretation, studies of [3H]hemicholinium-3 binding over a wider range of postmortem delay times (2-29 h) indicate a wide disparity, with some of the Alzheimer's group exhibiting normal or increased binding (28) , as would be expected from samples with the shortest postmortem delays. In any case, these findings indicate the importance of rapid autopsy to enable appropriate interpretation of the status of cholinergic function in Alzheimer's disease. In practical terms, the finding that upregulation of [3H]-hemicholinium-3 binding parallels the functional changes seen in choline transport into intact synaptosomes (12) also means that tissues frozen after rapid autopsy can serve for future evaluations of transporter expression, structure, and function, rather than limiting inquiries to the immediate evaluation of fresh tissue. Similar effects of postmortem delay may operate on other cholinergic markers, such as choline acetyltransferase, albeit to a lesser extent than for [3H]hemicholinium-3 binding. The degree of choline acetyltransferase deficit in cortical regions of the Alzheimer's disease group seen here (30-40%) is less than that generally found with standard autopsy material (1) (2) (3) 8) ; this suggests that the diseased tissue undergoes more rapid postmortem deterioration, in agreement with previous findings (12) .
These results have significant implications for the therapy of Alzheimer's disease. If an underlying defect in choline utilization leads to failure of cholinergic neurotransmission and an ever-increasing, and possibly pathologic, upregulation of impulse activity that worsens the metabolic consequences of the defect, then the appropriate intervention is to break this positive feedback loop. Numerous clinical reports where dietary choline loading has been attempted in an effort to increase cholinergic neurotransmission have been largely disappointing (3) , which would be predicted if the major defect is in choline utilization rather than choline availability. Pharmacological interventions to increase cholinergic tone in this case might be expected to produce short-term improvement in synaptic function but at the expense of accelerating neurodegeneration (1) . Based on our findings, the most appropriate therapeutic strategy might be to administer agents that reduce cholinergic impulse activity and thus diminish the neuron's demand for choline; the worsening of cholinergic neurotransmission and associated cognitive impairment could instead be offset by administering drugs that augment postsynaptic cholinergic function, such as cholinergic receptor agonists and cholinesterase inhibitors. Indeed, the rigorous testing of these strategies may be the ultimate test of the cholinergic hypothesis of cognitive impairment in Alzheimer's disease or, alternatively, could establish whether the loss of noncholinergic neurons is equally important (30, 31) .
